1 min read
Chief Medical Officer Summit -CMO 360°
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
1 min read
Whether you have a compound and need to get started on your IND, or want to recruit patients quickly to get your early phase trials running or just need medical writing or biostatistical support for your programs - Veristat can help. We provide impactful solutions on both a full-service or functional service basis.
Schedule a meeting by filling out the form on the right. Find out how we can help you advance your next clinical trial or regulatory submission to successful outcomes. Or learn more about our capabilities.
Wednesday 17th November/ 11.40 a.m
" The Role of Natural History Studies in Ultra-Rare Disease Trials– Takeaways from a Canavan Disease Gene Therapy Trial on Their Challenges, Benefits and Successes"
Speakers:
John Balser, PhD, President and Chief Biostatistician, Veristat
Rachel Smith, Portfolio Director, Veristat
Abstract:
Completing a natural history study in conjunction with an interventional study for ultra-rare diseases can be critical to understanding the disease and its progression. The data from the natural history can be essential to informing the design and outcome selection of the interventional study. We explore the challenges of setting up a natural history study with both retrospective and prospective data to develop a new rating scale for disease progression in Canavan disease, a rare and relatively unknown childhood disease.
Our experts will share their experience, successes, and lessons learned on :
Website: https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
1 min read
Apr 9, 2024 Veristat Events
Meet the Veristat team at Booth #3, April 17th and 18th in Boston
The Science-First CRO™ and Consultancy Ready to...
4 min read
Mar 22, 2024 Veristat Events
Don´t miss Veristat’s plenary presentation at the World Orphan Drug Congress (WODC), Boston, Thursday, April 25th at...